Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2020 Jan 9;7(1):ofaa005.
doi: 10.1093/ofid/ofaa005. eCollection 2020 Jan.

Risk Factors for Herpes Zoster Infection: A Meta-Analysis

Fawziah Marra  1 , Kamalpreet Parhar  1 , Bill Huang  1 , Nirma Vadlamudi  1
Affiliations
Review

Risk Factors for Herpes Zoster Infection: A Meta-Analysis

Fawziah Marra et al. Open Forum Infect Dis. .

Abstract

Background: The burden of herpes zoster (HZ) is significant worldwide, with millions affected and the incidence rising. Current literature has identified some risk factors for this disease; however, there is yet to be a comprehensive study that pools all evidence to provide estimates of risk. Therefore, the purpose of this study is to identify various risk factors, excluding immunosuppressive medication, that may predispose an individual to developing HZ.

Methods: The literature search was conducted in MEDLINE, EMBASE, and Cochrane Central, yielding case control, cohort, and cross-sectional studies that were pooled from January 1966 to September 2017. Search terms included the following: zoster OR herpe* OR postherpe* OR shingle* AND risk OR immunosupp* OR stress OR trauma OR gender OR ethnicity OR race OR age OR diabetes OR asthma OR chronic obstructive pulmonary disease OR diabetes. Risk ratios (RRs) for key risk factors were calculated via natural logarithms and pooled using random-effects modeling.

Results: From a total of 4417 identified studies, 88 were included in analysis (N = 3, 768 691 HZ cases). Immunosuppression through human immunodeficiency virus/acquired immune deficiency syndrome (RR = 3.22; 95% confidence interval [CI], 2.40-4.33) or malignancy (RR = 2.17; 95% CI, 1.86-2.53) significantly increased the risk of HZ compared with controls. Family history was also associated with a greater risk (RR = 2.48; 95% CI, 1.70-3.60), followed by physical trauma (RR = 2.01; 95% CI, 1.39-2.91) and older age (RR = 1.65; 95% CI, 1.37-1.97). A slightly smaller risk was seen those with psychological stress, females, and comorbidities such as diabetes, rheumatoid arthritis, cardiovascular diseases, renal disease, systemic lupus erythematosus, and inflammatory bowel disease compared with controls (RR range, 2.08-1.23). We found that black race had lower rates of HZ development (RR = 0.69; 95% CI, 0.56-0.85).

Conclusions: This study demonstrated a number of risk factors for development of HZ infection. However, many of these characteristics are known well in advance by the patient and clinician and may be used to guide discussions with patients for prevention by vaccination.

Keywords: age; herpes zoster; immunocompromised; meta-analysis; risk factors.

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
Screening of studies for inclusion into the study.
Figure 2.
Figure 2.
Pooled analysis of the risk of herpes zoster.
See this image and copyright information in PMC

References

    1. Weller TH. Varicella and herpes zoster. Changing concepts of the natural history, control, and importance of a not-so-benign virus. N Engl J Med 1983; 309:1434–40. - PubMed
    1. Cohen JI. Herpes zoster. N Engl J Med 2013; 369:255–263. - PMC - PubMed
    1. Oxman MN. Clinical manifestations of herpes zoster. In: Arvin AM, Gershon AA, eds. Varicella-Zoster Virus: Virology and Clinical Management. Cambridge: Cambridge University Press; 2000: pp 246–75.
    1. Somayaji R, Elliott JA, Sibbald RG. Dermatologic manifestations of herpes zoster. In: Watson CPN, Gershon AA, Oxman MN, eds. Herpes Zoster: Postherpetic Neuralgia and Other Complications: Focus on Treatment and Prevention. Cham: Springer International Publishing; 2017: pp 103–15.
    1. Kovac M, Lal H, Cunningham AL, et al. ; ZOE-50/70 Study Group Complications of herpes zoster in immunocompetent older adults: incidence in vaccine and placebo groups in two large phase 3 trials. Vaccine 2018; 36:1537–41. - PubMed